The Tübingen biotech company Curevac is working flat out on its production network for its corona vaccine, which has not yet been approved.
Now the pharmaceutical giant Novartis is also there.
Munich - The Tübingen-based pharmaceutical company Curevac has brought another partner on board for the production of its corona vaccine candidate.
The Swiss pharmaceutical company Novartis will produce up to 50 million doses by the end of the year, said Curevac on Thursday in Tübingen after the contract was signed.
In the coming year, Novartis should deliver 200 million cans.
According to the plans, deliveries from a Novartis plant in Kundl, Austria, should start in the summer, explained Curevac.
The active ingredient from the Baden-Württemberg company has been in crucial clinical studies since December.
Curevac only started the approval process for its corona vaccine candidate in February.
For this purpose, the responsible European Medicines Agency (EMA) was provided with the first data packages from the clinical studies as part of a rolling process.
According to earlier information, Curevac is hoping for approval in the second quarter.
Curevac: Biotech company builds powerful alliance
Curevac has been preparing for future large-scale commercial production of its vaccine for months and has formed alliances with other companies.
The German companies Bayer, Wacker and Rentschler as well as the British group GlaxoSmithKline will also manufacture the active ingredient.
According to the companies involved, Bayer will produce 160 million cans in the coming year, while Wacker and Rentschler will deliver over a hundred million cans a year.
GlaxoSmithKline is expected to contribute up to a hundred million doses of the globally marketed vaccine this year.
Curevac also cooperates with the British group in other ways, for example in the further development of corona vaccines.
